ERBB2 and breast carcinoma: Denkert and coworkers have performed a pooled analysis of 3771 breast cancer patients that were treated with neoadjuvant therapy and pertaining to all breast cancer subtypes; an increased TIL level predicted response to neoadjuvant therapy in all molecular subtypes and it was associated with a survival benefit in HER2-positive breast cancer and TNBC [435].